Skip to main content Back to Top
Advertisement

8/8/2022

Bumetanide Injection

Products Affected - Description

    • Bumetanide injection, Hikma, 0.25 mg/mL, 10 mL vial, 10 count, NDC 00641-6007-10
    • Bumetanide injection, Hikma, 0.25 mg/mL, 4 mL vial, 10 count, NDC 00641-6008-10
    • Bumetanide injection, Pfizer, 0.25 mg/mL, 10 mL vial, 10 count, NDC 00409-1412-10
    • Bumetanide injection, Pfizer, 0.25 mg/mL, 4 mL vial, 10 count, NDC 00409-1412-04

Reason for the Shortage

    • Athenex launched bumetanide injection in February 2022.
    • Hikma did not provide a reason for the shortage.
    • Pfizer has bumetanide injection on shortage due to increased demand.

Available Products

    • Bumetanide injection, Athenex, 0.25 mg/mL, 10 mL vial, 10 count, NDC 70860-0406-10
    • Bumetanide injection, Athenex, 0.25 mg/mL, 4 mL vial, 10 count, NDC 70860-0405-04

Estimated Resupply Dates

    • Hikma has bumetanide 0.25 mg/mL 4 mL and 10 mL vials on allocation.
    • Pfizer has bumetanide 0.25 mg/mL 4 mL and 10 mL vials on back order and the company estimates a release date of August 2022 for the 4 mL vials and February 2025 for the 10 mL vials.

Updated

Updated August 8, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created April 23, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.